The Highest Dose of Semaglutide Available in the UK

The decision you're actually facing: which dose is right, not which is highest

Most people searching for the highest semaglutide dose are really asking a slightly different question: will a higher dose produce better results for me? That's a reasonable thing to want to know. The short answer is that, in clinical trials, greater doses did produce greater average weight loss — but the jump from the standard 2.4 mg maintenance dose to the newer 7.2 mg ceiling was more meaningful for some participants than others.

The prescriber's job is to help you find the dose where the benefits clearly outweigh any side effects. That may be 2.4 mg. It may, over time and with evidence of good tolerance, be 7.2 mg. It will not be determined by which number sounds most effective. A question our prescribers hear most weeks is whether patients can simply start at the highest dose to get faster results, the honest answer is no, and attempting to do so tends to produce the kind of nausea and vomiting that causes people to stop treatment altogether. You can read more about how the full range of doses is structured on the Wegovy doses page.

The licensed titration pathway exists precisely because semaglutide slows gastric emptying, which is also what causes the GI side effects that are most prominent in the first few weeks. The 0.25 mg starting dose is not a therapeutic dose; it is a settling-in period, and if you want to understand exactly what the semaglutide daily dose looks like across that schedule, we cover that in detail separately. Each four-weekly step up (through 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and now potentially 3.6 mg and 7.2 mg) gives your system time to adapt before the next increase.

What the 7.2 mg approval actually changed

Until January 2026, the standard semaglutide maintenance dose for weight management was 2.4 mg weekly. The MHRA then approved 7.2 mg as a higher maintenance dose (initially supplied as three 2.4 mg pens per week) before confirming on 14 April 2026 that a dedicated single-dose 7.2 mg pen had been approved. This pen has an auto-dosing mechanism, a built-in covered needle, and locks after use, making administration more straightforward at this higher dose level.

The trial data behind this approval showed an average weight reduction of approximately 20.7% over 72 weeks at 7.2 mg. That compares with roughly 15% at 2.4 mg in the STEP 1 trial, a meaningful difference, though the head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, still showed tirzepatide producing greater average weight loss than semaglutide 2.4 mg over 72 weeks. The 7.2 mg dose narrows that gap considerably, and our page on the highest dose of semaglutide you can take goes into the clinical background behind where that ceiling now sits. For a fuller look at how this compares to the established 2.4 mg ceiling, the highest dose of Wegovy page goes into more depth on the clinical background.

One important licensing point: the 7.2 mg dose is approved for adults with a BMI of 30 or above only. It is not licensed for the cardiovascular indication or for the newly approved MASH (fatty liver disease) use. The starting dose remains 0.25 mg regardless of the intended maintenance target, and the titration schedule is not accelerated simply because the eventual goal is 7.2 mg.

Side effects at higher doses: what changes as you increase

GI side effects (nausea, loose stools, constipation, reflux) are the most common reason people do not reach the highest semaglutide dose. They tend to peak after a dose increase and settle within roughly one to two weeks for most people, but this pattern varies. At 7.2 mg, the incidence of GI side effects is higher than at 2.4 mg, which is why clinical oversight at each step matters.

There are also less common effects worth knowing about. The MHRA highlighted acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines: severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention rather than waiting to see if it passes. Gallbladder problems, injection-site reactions, and dizziness are also documented. You can report any suspected side effect (at any dose) through the MHRA Yellow Card scheme.

Contraception is also worth mentioning here. For women on oral contraceptives, the NHS advises adding a non-oral method during the first four weeks of treatment and for four weeks after each dose increase, because semaglutide slows gastric emptying in a way that may reduce pill absorption. If you are pregnant, breastfeeding, or planning a pregnancy, semaglutide is not recommended. Under-18s are not a licensed population for this treatment.

How to approach the dose ceiling: what your prescriber will look at

Reaching 7.2 mg is not simply a matter of waiting long enough. Prescribers look at two things at every review: how much weight you have lost, and how well you are tolerating the current dose. NICE guidance on semaglutide for weight management includes a checkpoint at six months on the maintenance dose, if weight loss has been less than 5%, the case for continuing at that dose (let alone increasing it) is reviewed.

Availability of specific doses and pen formats is also a practical consideration and is confirmed at the point of consultation, not assumed. The semaglutide highest dose for weight loss page covers the eligibility picture in more detail, and if you want to understand what the full private-treatment journey looks like before speaking to a clinician, the weight loss treatment overview sets out the options clearly.

Private treatment with a GPhC-registered pharmacy gives you access to a prescriber without a referral or a waiting list, subject to clinical suitability. If you are curious about what Wegovy pricing looks like in practice, the picture is more straightforward than many people expect. All told, the right dose for you is determined by a clinician who has reviewed your medical history, not by the number at the top of a leaflet. If you'd like that conversation, speak to our prescribers through a free consultation, reviewed the same working day.